ABSTRACT: Antagonism of  v  6 is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an  v  3 antagonist lead and through simple variation in the nature and position of aryl substituent, the discovery of compounds with improved  v  6 activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery programme. Compounds 33S and 43E1 are pan  v antagonists having ca 100 nM potency against  v  3,  v  5,  v  6 and  v  8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC50 values between the integrins in question) for  v  3 and  v  5 .
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Once diagnosed, life expectancy for patients with idiopathic pulmonary fibrosis (IPF) is usually only a few years and the mortality rate exceeds that of many cancer indications. 1,2 A recent study in the UK also suggests that the incidence of IPF is rising with > 5,000 new cases diagnosed each year. 3 Although pirfenidone is now marketed for the treatment of IPF in some countries, 4 there remains an urgent need for effective new medicines. Recent research into IPF together with estimated peak sales for an effective treatment at around $2 billion per annum, have driven significant commercial activity around potential biological and small molecule fibrosis assets in the pharmaceutical sector. 5 There is now reasonable evidence that the RGD (arginineglycine-aspartic acid) integrin receptor  v  6 may play an important role in the initiation and progression of IPF inter alia. 6, 7 This receptor is predominantly expressed in injured lung tissue and inhibition of the receptor with  v  6 antibodies or its absence in knock-out mice leads to substantial protection from the development of fibrosis in both bleomycin 8 and radiation 9 induced animal models. Selective  v  6 antibodies are in development for fibrotic diseases. 5 The  v  6 receptor is a cell surface heterodimeric receptor composed of a non-covalently bound complex between the  v and  6 proteins. Three closely related integrins where only the  subunit is varied are  v  3,  v  5 and  v  8 . Despite substantial research and drug discovery over the last decade on antagonists of the  v  3 receptor for osteoporosis and other indications, [10] [11] [12] [13] there is remarkably little literature on potent and selective small molecule antagonists of  v  6 . The selectivity profiles of the  v  3 antagonists in the literature rarely include cross-screening data against  v  6 or other  v integrins with the exception of a Pfizer series of compounds for which a broad range of integrin data is reported (although the potencies are quite weak as  v  6 antagonists). 14 Other exceptions are the Merck KGa, 15 Merck AG, 16 Merck, 17 Monsanto 18 compounds (14, Figure 1 ) and JNJ-26076713 19 (where the Arg guanidine and Asp acid mimetics are apparent at the either end of a chain) and very recently  v integrin data in patents from Ruminski and Griggs at the University of St Louis. 20 We describe here detailed structure activity relationship (SAR) studies of novel analogues of 4 describing for the first time their profiles against  v  3 ,  v  5 ,  v  6 and  v  8 in cell adhesion assays. By varying the substituent pattern on the aryl ring, we have discovered pan  v antagonists such as 33S and 43E1 ("pan" defined here as having antagonism against all the  v integrins tested, namely
antagonists with partial selectivity (defined as at least a 0.7 log difference in pIC50 values between the integrins in question) for  v  3 (such as 27) and partial selectivity for  v  5 (such as 35). The profiles of antagonists with partial dual selectivity for  v  3 and  v  5 (such as the known compounds 4 17 and 42 17 ) and are also described. Seemingly fairly subtle changes on just the aryl ring of the structures exert a profound effect on the overall selectivity profile, and in this series, it appears considerably more marked than in the Merck KGa series. 15 Measured lipophilicity values for compounds (chrom. logD) 21 are also provided. (When the sum of chrom. log D plus aromatic ring count is <6, there is an increased likelihood of a compound being more developable as an oral drug). 21 2 Figure 1 . Exemplar  v integrin antagonists from the literature together with selected reported activities and activities in the assays described herein.
The combination of the  v  6 activity of these compounds with their physicochemical properties, which are commensurate with potential oral bioavailability, identifies them as high quality starting points for a drug discovery programme and amongst the best currently known in the literature. Derivatives of ethyl or methyl 3-amino-3-phenylpropanoate 7 were prepared in two steps from the appropriate aldehydes 5 by the Rodionov reaction 22 followed by esterification to 7, or were purchased from commercial sources (Scheme 1). Ethyl 3-amino-3-(3-pyridyl)propanoate 10 was made in the same way from 3-formylpyridine. Indane-5-carboxaldehyde was prepared in 38% yield by treatment of indane with hexamethylenetetramine/TFA as described by Arora, et al. 23 Hydrogenation of amino ester hydrochloride 7 (R = H) gave the cyclohexyl derivative 8. The 4-cyano analogue 7 (R = 4-CN) was obtained in low yield after the esterification owing to a competing Pinner reaction. To circumvent this problem in the case of the 3-cyano analogue, the amino group was protected as the benzyl carbamate (CBZ), followed by esterification under mildly basic conditions and CBZ-group deprotection to give 9. Scheme 1. Synthesis of 3-aryl-3-aminopropanoic ester intermediates. Reagents Amide coupling of 1,8-naphthyridin-2-yl)pentanoic acid 11 17 to amino esters 7 (R = 2-OMe, 3-Me, 3-OCF 3 and 3,4-(OMe) 2 , Scheme 2) gave the corresponding esters 12 in 31-67% yields. Selective hydrogenation of the naphthyridine ring gave the corresponding compounds 13 (R = 2-OMe, 3-Me, 3-OCF 3 and 3,4-(OMe) 2 ) (44-96%). For all the other compounds, the tetrahydronaphthyridine pentanoic acid 14 17 could be coupled directly to the amino esters 7-9 to give compounds 13. Hydrolysis of the esters 13 under basic conditions then afforded the target acids (see Table 1 for numbering). For the preparation of the single enantiomers of 33, commercially available assigned (R) and (S) enantiomers of the 3-CF 3 amino ester 7 were used. For the enantiomers of 37 and 43, the precursor ethyl esters 13 (R = 3,5-Cl 2 and 3-CF 3 ,4-Cl respectively) were separated by preparative chiral HPLC and then hydrolysed to afford the target compounds.
The compounds were tested in  v  6,  v  3,  v  5 and  v  8 cell adhesion assays as previously described. 24 Lipophilicity was determined using an HPLC chromatographic logD protocol. 21 Preliminary unpublished work led to the selection of template 4 as suitable for exploring  v  6 activity and in particular investigating what the impact of different aryl substituents might be. Although structure activity relationships (SAR) have been described by Merck for this template, 17 these predominantly relate to  v  3 with little, if any,  v  6 data published. Data from the present study are presented in Table 1 . In order to establish preliminary  v SAR rapidly, fluoro, chloro, methyl and methoxy analogues were prepared in the ortho, meta and para positions.
The parent phenyl compound 15 is a micromolar  v  6 antagonist and substantially more potent against  v  3 and  v  5 .
25,26
In every case, the fluoro, chloro, methyl and methoxy com- 27 Based on these data, the next iteration of analogues focussed on further mono-substituents in the meta and para positions as these showed more consistent  v  6 activity and are more synthetically accessible compared to the ortho analogues. Data from further mono-para substituents were explored (Table 1, 27−31). Activities against  v  6 are similar (pIC 50 6.16.4) despite varying size and electronic properties. In contrast, there is a ten-fold range in activity against  v  3 (pIC 50 6.67.6) with a p-OMe 26 showing the most potent activity and a p-CF 3 28 the least suggesting the electronic properties of the substituent may play a role. A similar pattern is seen with  v  5 whereas antagonism of  v  8 is flat and essentially similar to  v  6 . The p-CN analogue 27 suggests some selectivity for  v  3 . However these data do not indicate mono substitution in the para position is useful for increasing  v  6 activity and so no further analogues were prepared. In contrast, mono-substitution in the meta-position (Table 1 3 analogue 33 (racemate pIC 50 7.0) were prepared from commercially available pure (S) and (R) enantiomers of 7 thus allowing 33S and 33R to be assigned as the (S) and (R) trifluoromethyl enantiomers respectively and with corresponding  v  6 pIC 50 values of 7.1 and 5.2. Given the high sequence homology between  v  3 and  v  6 , this is consistent with the more potent m-fluoro analogue 4 against  v  3 also having (S) stereochemistry as described elswhere. 28 An approximately tenfold range in activity for m-substituents is also seen for  v  3 (pIC 50 6.47.5) and  v  5 (pIC 50 7.17.8) with antagonist activities generally being greater than those observed for  v  6 . The SAR is idiosyncratic suggesting that multiple low energy binding conformations may be possible. As seen with the para-substituents, the  v  8 SAR essentially tracks the  v  6 SAR.
respectively)). The enantiomers of the most potent m-CF
The m-CN analogue 32 shows an approximate 0.71.4 log selectivity for  v  5 (pIC 50 7.4) over the other  v integrins. The m-CF 3 analogue 33S is the most potent antagonist against  v  6 (pIC 50 7.1) and equipotent against  v  3 ,  v  5 and  v  8 (pIC 50 7.0, 7.2 and 6.9). Meta-substitution is clearly highly influential on the selectivity profile and further work is ongoing. Given the impact of mono aryl substitution on potency and selectivity, we decided to explore also the impact of disubstitution because if there are multiple binding pockets in this region of the active site, then synergistic effects might be observed. As the meta position had proved most sensitive we preserved substitution at this position whilst varying the position of the second substituent selecting analogues (35−43) which could be prepared from readily available starting materials.
A greater range in potency was seen with di-substituted analogues compared with mono substituted analogues. Preparation of substitution patterns of dichloro analogues gives an interesting range of selectivity profiles. The 2,3-dichloro 35 shows micromolar potency for  v  5 and ten-fold selectivity over the other  v integrins. The 3,4-dichloro 36 and the 3,5-dichloro 37 restore  v  6 activity (pIC 50 6.7 and 6.8 respectively) with the 3,5 analogue 37 being a pan  v antagonist. Separation of the 3,5-Cl 2 enantiomers 29 gave  v  6 pIC 50 activities of 6.8 (37E2) and 5.2 (37E1) with 37E2remaining predominantly a pan antagonist. As expected, the known 3,4-methylenedioxy analogue 42 17 has approximately nanomolar potency and greater than ten-fold selectivity for  v  3 and  v  5 over  v  6 and  v  8 ; it also has increased potency by 0.60.7 log units over the 3,4-dimethoxy substituents 41 which is less selective for  v  3 and  v  5 . The presence of the oxygens is important as both the corresponding indane 39 and 3,4-dimethyl substituents 38 are almost a log unit less potent against  v  3 and  v  5 and are also less selective. The same applies to the 3,4-dichloro analogue 36. The 3-trifluoromethyl-4-chloro analogue 43 is also a pan  v antagonist with the more active enantiomer 43E1 29 having a similar profile. Presented here are SAR studies of a series of integrin antagonists against  v  3 ,  v  5 ,  v  6 and  v  8 . Although 4 and 42 have previously been described as  v  3 antagonists, 17 the studies described here show a more detailed picture of their profile with both compounds potent against  v  3 but also being equipotent against  v  5 . The SARs presented here clearly show that by simple variation of the position and nature of the aryl substituent, the cell adhesion potency against  v  6 can be increased and, comparatively, potency against  v  3 and  v  5 reduced. Comparison of the lead compounds described here (e.g. 33S and 43E1) with the standards 1 and 3 from the literature (cf. Figure 1) show they have similar  v  6 activity but with structural features perhaps more commensurate with oral bioavailability properties. Their lipophilicities are reasonable (chrom. logD values of 2.72 for 33S and 3.28 for 43E1) and they possess good permeability and solubility (data not shown). Indeed analogues of these compounds prepared by Merck have been shown to have good oral bioavailability in dog. 17, 28 Although a crystal structure of  v  6 is currently not available, a homology model is available 30 and the  v  3 crystal structure has been described. 31 From the latter, it is known that the RGD motif (or ligand mimetic) binds at the interface between the  v and the  3 (or  6 ) subunits with the arginine (or mimetic) binding to the  v unit and the aspartic acid (or mimetic) binding to the  3 (or  6 ) subunit. There is considerable sequence similarity between the  3 and  6 subunits so the gross topology is also likely to be similar. Based on this, an extended conformation for these ligands in  v  6 is likely to be the conformation for antagonism and is also consistent with why small differences in aryl group substitution might have the profound impact on the selectivity between the different  v integrins observed.
Further studies to improve  v  6 potency are underway. Clearly sufficient potency is required to drive an antifibrotic response at a realistic clinical dose but a compromise may be required between the ideal potency and ideal selectivity. Although our focus here is IPF, a pan  v antagonist has recently been reported 32 as being efficacious in a number of models of fibrotic diseases (see supporting information).
Described here are SAR relationships against  v  3 ,  v  5 ,  v  6 and  v  8 with the aim of ultimately identifying an orally bioavailable selective and potent  v  6 for treating IPF. The lead compounds 33S and 43E1 have been derived from  v  3 antagonists to pan  v antagonists with antagonisms around pIC 50 7 (100 nM). This has been achieved whilst maintaining physicochemical properties commensurate with oral bioavailability. Compounds which are partially selective for  v  5 have also been identified. Further studies will be reported in due course.
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Notes
The results in this paper are from fourth year undergraduate research projects at the University of Nottingham in collaboration with GlaxoSmithKline with the aim of giving students experience of industrial medicinal chemistry. The selection of the targets and the syntheses were carried out predominantly by the students under the guidance of the last three authors.
